Guardant Health (MIL:1GH) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1GH Guardant Health Inc MIL:1GH
43 GF Score
Price €132.02
GF Value €53.48
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Guardant Health Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Guardant Health Quality Rank Related Terms

MIL:1GH
43GF Score
Guardant Health Inc MIL:1GH
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Guardant Health (MIL:1GH) Overvalued in 2026?

Based on GuruFocus' analysis, Guardant Health stock appears to be overvalued. The current stock price of €132.02 is trading 146.9% above its estimated GF Value™ of €53.48. GuruFocus considers Guardant Health to be Significantly Overvalued.

Key valuation signals for MIL:1GH:

  • Quality Rank:
  • GF Value™: €53.48 vs. price of €132.02 (146.9% above fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the MIL:1GH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guardant Health Business Description

Other Exchanges GH:USA5GH:Germany
Address 3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
43GF Score

Get the complete analysis for MIL:1GH

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€132.02
Price
€53.48
GF Value